With over 0.14 million Akari Therapeutics Plc (AKTX) shares trading Friday and a closing price of $0.50 on the day, the dollar volume was approximately $69724.0. The shares have shown a negative half year performance of -41.20% and its price on 01/20/23 lost nearly -1.98%. Currently, there are 74.45M common shares owned by the public and among those 71.55M shares have been available to trade.
LUX IM – Global Medtech owns 98680.0 shares of the company’s stock, all valued at over $46380.0.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Shares of Akari Therapeutics Plc (NASDAQ: AKTX) opened at $0.50, down -$0.01 from a prior closing price of $0.51. However, the script later moved the day high at 0.5371, down -1.98%. The company’s stock has a 5-day price change of -7.36% and 2.42% over the past three months. AKTX shares are trading 6.38% year to date (YTD), with the 12-month market performance down to -65.04% lower. It has a 12-month low price of $0.38 and touched a high of $1.61 over the same period. AKTX has an average intraday trading volume of 76.83K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.70%, -3.49%, and -41.93% respectively.
Institutional ownership of Akari Therapeutics Plc (NASDAQ: AKTX) shares accounts for 13.70% of the company’s 74.45M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $37.99M and a beta (3y monthly) value of 1.44. The earnings-per-share (ttm) stands at -$0.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.45% over the week and 14.06% over the month.
Analysts forecast that Akari Therapeutics Plc (AKTX) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2022. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.14 a year ago.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Akari Therapeutics Plc (AKTX) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AKTX, a number of firms have released research notes about the stock. B. Riley FBR stated their Buy rating for the stock in a research note on January 04, 2019, with the firm’s price target at $2.50-$3. B. Riley FBR Inc. coverage for the Akari Therapeutics Plc (AKTX) stock in a research note released on February 08, 2018 offered a Neutral rating with a price target of $3. William Blair was of a view on September 22, 2017 that the stock is Outperform, while Chardan Capital Markets gave the stock Neutral rating on May 31, 2017, issuing a price target of $6. Chardan Capital Markets on their part issued Sell rating on April 17, 2017.
